Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.
Also called NCT01872039
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 163 participants
- Sponsor
- Astellas Pharma China, Inc.
- Registry
-
NCT01872039
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01872039. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients
- Condition
- Hypertension Emergency
- Condition
- End-organ Damage
- Intervention (Drug)
- Perdipine injection
- Lead sponsor
- Astellas Pharma China, Inc.
Record details
- Record id
cardio:ct-nct01872039- Content hash
e88fc01542a38d4182d9213874306908b1a33cda446fc49f131015742a86147f